Ownership and insider activity for Oncolytics Biotech Inc. (ONCY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
Price
| Price | $0.77 |
| Market Cap | $77M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-01 | McAdory John Bearden | 500,000 | $485K | |
| 2026-06-01 | Glover Stephen C. | |||
| 2026-03-11 | Parsons James T. | P-Purchase | 10,000 | $10K |
| 2026-03-12 | Kelly Jared | P-Purchase | 5,050 | $5K |
| 2026-02-12 | Kelly Jared | P-Purchase | 29,500 | $25K |
| 2026-02-11 | Kelly Jared | P-Purchase | 5,600 | $5K |
| 2026-02-12 | Look Kirk | P-Purchase | 12,000 | $10K |
| 2026-02-12 | Pisano Wayne | P-Purchase | 30,000 | $25K |
| 2026-02-12 | Heineman Thomas Charles | P-Purchase | 12,132 | $10K |
| 2026-02-12 | Brown Deborah Margaret | P-Purchase | 25,000 | $21K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.0M | $11.8M | $13.7M | $14.1M | $31.2M | $41.3M | $11.7M | $34.9M | $15.9M | $7.1M |
| Short-term Investments | $2.1M | 0 | 0 | 0 | 0 | 0 | $20.5M | 0 | 0 | 0 |
| Receivables | $54406 | $4.8M | $51650 | 0 | 0 | $866000 | $521000 | $15000 | $68000 | $786230 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $14.4M | $17.8M | $14.5M | $18.9M | $33.7M | $44.9M | $35.7M | $38.2M | $18.9M | $9.4M |
| Property, Plant & Equipment | $319955 | $333441 | $412736 | $727481 | $609132 | $976000 | $652000 | $647000 | $1.3M | $1.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $14.8M | $18.2M | $14.9M | $19.7M | $34.3M | $45.9M | $37.3M | $38.8M | $20.2M | $10.4M |
| Accounts Payable | $4.1M | $3.5M | $1.8M | $3.2M | $1.8M | $594000 | $2.3M | $1.1M | $1.1M | $4.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.1M | $5.2M | $2.8M | $12.9M | $2.7M | $2.7M | $3.9M | $4.2M | $6.7M | $8.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.1M | $9.9M | $8.7M | $19.8M | $9.6M | $9.8M | $10.8M | $11.3M | $14.2M | $15.6M |
| Retained Earnings | -$278.8M | -$294.4M | -$311.5M | -$344.6M | -$367.1M | -$393.4M | -$418.3M | -$446.0M | -$477.7M | -$589.3M |
| Total Equity | $10.7M | $8.3M | $6.2M | -$107894 | $24.8M | $36.1M | $26.5M | $27.6M | $6.0M | -$5.2M |
| Total Debt | 0 | 0 | 0 | $506275 | $402059 | $655000 | $373000 | $423000 | $1.1M | $772509 |
| Net Debt | -$14.1M | -$11.8M | -$13.7M | -$13.6M | -$30.8M | -$40.6M | -$31.8M | -$34.5M | -$14.9M | -$6.4M |
| Working Capital | $10.4M | $12.6M | $11.6M | $6.1M | $31.0M | $42.2M | $31.7M | $33.9M | $12.2M | $1.0M |
Financial Health
| Debt / Equity | -0.07 |
| Current Ratio | 1.35 |
Profitability
| Return on Equity | 1020.21% |
| Return on Invested Capital | -1480.50% |
| Return on Assets | -498.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATOS · CLNN · COYA · IMMX · MGNX · SRZN · TIL
Explore sector: Healthcare · Biotechnology
More sections of ONCY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks